The ENCHANTMENT HIV Study

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

July 9, 2025

Study Completion Date

July 9, 2025

Conditions

HIV/AIDSHeart Failure With Preserved Ejection Fraction

Interventions

DRUG

Sacubitril-Valsartan 49-51Mg Oral Tablet

By mouth twice daily

DRUG

Placebo oral tablet

Placebo oral tablet By mouth twice daily

Trial Locations (1)

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

NCT04153136 - The ENCHANTMENT HIV Study | Biotech Hunter | Biotech Hunter